Humanin: The Mitochondrial-Derived Peptide With Broad Cytoprotective Research

For informational purposes only. This article does not constitute medical advice. Consult a qualified healthcare provider for any health-related decisions.

What Is Humanin?

Humanin is a 24-amino-acid peptide (sequence: MAPRGFSCLLLLTSEIDLPVKRRA) that holds a unique distinction in biology — it is encoded by mitochondrial DNA rather than nuclear DNA. Specifically, humanin is transcribed from a short open reading frame (sORF) within the 16S ribosomal RNA gene of the mitochondrial genome. First identified in 2001 by Dr. Yuichi Hashimoto and colleagues while screening for factors that could protect neurons from amyloid-beta toxicity in Alzheimer's disease, humanin inaugurated an entirely new class of bioactive molecules: mitochondrial-derived peptides (MDPs).

The discovery of humanin challenged the prevailing view that the mitochondrial genome's only functional products were 13 electron transport chain subunits, 22 tRNAs, and 2 rRNAs. It is now understood that the mitochondrial genome harbors multiple sORFs encoding biologically active peptides, including the MOTS-c and SHLPs (small humanin-like peptides) families. Together, these MDPs represent a novel form of retrograde signaling from mitochondria to the cell and the organism. For broader context on mitochondrial peptides, see our guide to mitochondrial peptides.

Property	Detail
Peptide Name	Humanin (HN)
Amino Acids	24
Molecular Weight	~2,687 Da
Encoded By	Mitochondrial DNA (16S rRNA gene region)
Discovery	2001, screening for neuroprotective factors (Hashimoto et al.)
Receptors	CNTFR/WSX-1/gp130 trimeric complex; FPRL1/2; intracellular targets
Potent Analog	HNG (S14G substitution, 1,000x more potent)
FDA Status	Not approved; preclinical

Mechanism of Action

Humanin exerts its biological effects through multiple mechanisms, reflecting its role as a broad-spectrum cytoprotective signal from stressed or aging mitochondria.

Extracellular Receptor Signaling

• Trimeric receptor complex: Humanin binds a heterotrimer composed of CNTFR (ciliary neurotrophic factor receptor), WSX-1 (IL-27 receptor alpha), and gp130 (the common signaling subunit of IL-6 family cytokines). Activation of this complex triggers JAK/STAT3 signaling, which promotes cell survival gene expression.
• FPRL1/FPRL2: Humanin also binds formyl peptide receptor-like 1 and 2 (FPRL1/FPRL2), G-protein-coupled receptors involved in immune cell chemotaxis and inflammation resolution.

Intracellular Mechanisms

• BAX binding: Humanin directly binds BAX, the pro-apoptotic Bcl-2 family protein, preventing its translocation to the mitochondrial outer membrane and blocking the intrinsic apoptotic pathway. This represents a direct anti-apoptotic mechanism.
• IGFBP-3 interaction: Humanin binds insulin-like growth factor binding protein 3 (IGFBP-3), modulating IGF-1 signaling and potentially influencing the growth hormone/IGF-1 axis — a pathway with established links to aging and longevity.
• tBID neutralization: Humanin has been shown to interact with truncated BID (tBID), another pro-apoptotic molecule, further reinforcing its anti-apoptotic activity.

Research Findings

Neuroprotection and Alzheimer's Disease

Humanin was discovered through its ability to protect neurons from amyloid-beta (Abeta) toxicity, and neuroprotection remains its most extensively studied property. In cell culture models, humanin and its potent analog HNG (S14G substitution, approximately 1,000-fold more potent) protect neurons from Abeta-induced apoptosis at picomolar to nanomolar concentrations. In transgenic Alzheimer's mouse models (APP/PS1), humanin treatment has improved cognitive function (Morris water maze performance), reduced amyloid plaque burden, and decreased neuroinflammation markers.

Cardioprotection

Humanin has demonstrated cardioprotective effects in ischemia-reperfusion models. In mouse and rat models of myocardial infarction, humanin administration reduced infarct size, improved left ventricular function, and decreased cardiomyocyte apoptosis. These effects appear to be mediated through both the STAT3 survival pathway and direct BAX inhibition.

Metabolic Regulation

Circulating humanin levels are inversely correlated with insulin resistance and metabolic syndrome features in human observational studies. In animal models, humanin administration improved insulin sensitivity, reduced hepatic glucose output, and modulated lipid metabolism. These metabolic effects may be mediated through IGFBP-3 interaction and modulation of the GH/IGF-1 axis.

Age-Related Decline

Multiple studies have documented that circulating humanin levels decline with age in humans, with the decline accelerating after approximately age 40. This age-related decrease parallels declining mitochondrial function and increasing susceptibility to age-related diseases. The correlation has led to the hypothesis that humanin decline may be both a marker and a mediator of mitochondrial aging — reduced MDP signaling may impair the organism's cytoprotective capacity as mitochondrial function deteriorates.

Safety and Tolerability

As an endogenous peptide, humanin has inherent biological compatibility. Animal studies using exogenous humanin and HNG administration have not reported significant adverse effects. However, formal pharmacokinetic and toxicology studies in humans have not been conducted. Theoretical considerations include the potential consequences of chronic anti-apoptotic signaling (impaired clearance of damaged cells, potential tumor promotion) and the effects of modulating the GH/IGF-1 axis through IGFBP-3 interaction.

The short half-life of native humanin in circulation (minutes) presents pharmacokinetic challenges for therapeutic development, necessitating either frequent dosing, sustained-release formulations, or the use of stabilized analogs such as HNG.

Regulatory Status

Humanin is not FDA-approved for any indication. It has not entered formal clinical trials. The compound and its analogs are available through research peptide suppliers for preclinical investigation. Clinical translation faces several challenges including the need for potent, metabolically stable analogs; identification of the most appropriate therapeutic indications; and determination of optimal dosing strategies for chronic cytoprotective therapy.